Intraretinal hyperreflective foci, intraretinal hard exudates, and epiretinal membrane formation were lower after treatment with faricimab (Vabysmo) compared with aflibercept (Eylea) for patients with ...

This post hoc analysis of two trials compared faricimab and aflibercept in patients with diabetic macular edema who had baseline vision of 20/50 or worse. Researchers randomly assigned patients (1:1:1 ...

Faricimab (Vabysmo) showed greater fluid reduction compared with high-dose aflibercept (Eylea) at 12 weeks in matched analyses of diabetic macular edema (DME) and age-related macular degeneration (AMD ...

Please provide your email address to receive an email when new articles are posted on . The post hoc analysis of the YOSEMITE and RHINE studies found similar visual acuity results between patients ...

Please provide your email address to receive an email when new articles are posted on . YOSEMITE and RHINE investigated faricimab in patients with diabetic macular edema. In both studies, the drug was ...

Faricimab given every eight weeks and at personalised dosing intervals of up to 16 weeks demonstrated non-inferior visual acuity gains compared to aflibercept given every eight weeks in both studies ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) today announced detailed results from four Phase III studies of its investigational ...

Since July 2024, faricimab has also been approved in Europe for the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion. The German Institute for Quality and ...

Credit: Shutterstock. Findings showed faricimab was associated with rapid drying of retinal fluid. The Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the ...

Faricimab, an experimental drug, could reduce the number of injections needed to treat both age-related macular degeneration (AMD) and diabetic macular edema (DME), phase 3 trials suggest. Faricimab's ...